Kalufar

Bicalutamide, the active ingredient in Kalufar, is a nonsteroidal antiandrogen presented as an oral formulation for oral use. It is employed in the management of advanced and hormone‑sensitive prostate cancer, where it blocks androgen‑driven tumor growth.

GNH USA supplies Kalufar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Bicalutamide acts on androgen‑dependent pathways and is indicated for several forms of prostate cancer.

- Advanced prostate cancer: slows disease progression by inhibiting androgen signaling. - Metastatic prostate cancer: reduces tumor growth and spread. - Hormone‑sensitive prostate cancer: blocks testosterone‑driven cell proliferation.

Bicalutamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes: transient feeling of warmth. - Gynecomastia: enlargement of breast tissue in males. - Decreased libido: reduced sexual desire. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Liver toxicity: elevated liver enzymes or hepatitis. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pulmonary embolism: blood clot in the lungs. - Severe skin rash: Stevens‑Johnson syndrome. - Blood clotting disorders: deep vein thrombosis. - Adrenal insufficiency: abnormal cortisol production.

Before initiating therapy, several safety considerations are recommended.

- Liver monitoring: assess hepatic function regularly. - Cardiovascular assessment: evaluate risk of thrombosis. - Hormone level checks: monitor testosterone and estrogen changes. - Hypersensitivity avoidance: discontinue if allergic reaction occurs. - Elderly caution: adjust monitoring due to comorbidities. - Store at ambient temperature: keep in the original pack, protect from moisture.

Bicalutamide can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase toxicity. - Warfarin: may enhance anticoagulant effect and raise INR. - LHRH agonists: additive antiandrogen effect may increase side‑effects. - Hormonal contraceptives: reduced efficacy due to altered hormone metabolism.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise plasma concentrations. - Other antiandrogens (e.g., flutamide): risk of cumulative toxicity. - Statins metabolized by CYP3A4: monitor for muscle symptoms. - Antidepressants (SSRIs): watch for increased fatigue. - Diuretics: monitor electrolyte balance.